Unlike expensive positron emission tomography (PET) scans or invasive lumbar punctures, the new blood test measures the ratio of two proteins, pTau217 and ß-Amyloid 1-42, which are implicated in ...

Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with ...

The FDA has granted 510 (k) marketing clearance to the first in vitro blood-based biomarker diagnostic device for Alzheimer’s disease. Fujirebio’s Lumipulse G pTau217/ -Amyloid 1-42 Plasma ...

The US Food and Drug Administration (FDA) has awarded 510 (k) clearance to Fujirebio’s Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio in vitro diagnostic (IVD) test for evaluating amyloid ...

The Food and Drug Administration (FDA) announced Friday it had cleared a new test to help diagnose adults with Alzheimer’s disease, the first diagnostic tool that uses a blood draw to check for ...

The Lumipulse G Plasma Ratio Test offers a new way to detect signs of Alzheimer's disease by identifying plaque proteins in the blood. Dr. Celine Gounder joins to explain how this could make early ...

The FDA noted the risk of false positive test results from Lumipulse, which could lead to inappropriate diagnosis and unnecessary treatment.

The test, called the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, is for adults 55 and older who are showing signs and symptoms of Alzheimer’s disease, the FDA announced Friday.

The company plans to make the diagnostic available to physicians and researchers this summer, expanding its portfolio beyond ...

Quest Diagnostics has signed up to offer a blood test that can help diagnose Alzheimer’s disease, following its FDA clearance earlier this year. | The Lumipulse G blood test measures the ratio between ...

On Friday, the Food and Drug Administration (FDA) cleared the first blood test for the disorder. Fujirebio Diagnostics' Lumipulse measures the ratio of two proteins that correlate with the ...